MR - Eyes For Cancer: Looking Within An Impenetrable Disease

NMR in Biomedicine

Volumn 26, Issue 7, 2013, Pages 745-755

  Penet, Marie France ^a   Artemov, Dmitri ^a,b   Farahani, Keyvan ^c   Bhujwalla, Zaver M ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; MR probes; Receptors imaging; Theranostics; Tumor microenvironment

Indexed keywords

CANCER; CRITICAL COMPONENT; IMAGE-GUIDED DIAGNOSIS; IMAGE-GUIDED TREATMENTS; MULTI-FUNCTIONAL NANOPARTICLES; MULTI-MODALITY IMAGING; THERANOSTICS; TUMOR MICROENVIRONMENT;

DIAGNOSIS; MAGNETIC RESONANCE IMAGING; MOLECULAR BIOLOGY; MOLECULAR IMAGING; PROBES;

DISEASES;

(IMIDAZOL 1 YL)3 ETHYOXYCARBONYLPROPIONIC ACID; 2 (IMIDAZOL 1 YL)SUCCINIC ACID; 2 NITRO ALPHA [(2,2,2 TRIFLUOROETHOXY)METHYL]IMIDAZOLE 1 ETHANOL; CD133 ANTIGEN; DENDRIMER; ESTRADIOL 17 YLETHYNYL(PYRIDINE 2,6 BIS(METHYLENENITRILO)]TETRAKIS; ESTROGEN RECEPTOR; FLUOROURACIL; GADOLINIUM; GADOLINIUM PENTETATE; HEXAMETHYLDISILOXANE; INTEGRIN; MANGANESE EPPT SIBIRC5; NANOCARRIER; NANOPARTICLE; NITROIMIDAZOLE DERIVATIVE; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXYHEMOGLOBIN; RADIOPHARMACEUTICAL AGENT; SMALL INTERFERING RNA; SODIUM CARBONATE; SURVIVIN; TEMOZOLOMIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; ASTROCYTOMA; BLOOD OXYGENATION; BOLD SIGNAL; BREAST CANCER; CANCER CELL; CANCER DIAGNOSIS; CARBON NUCLEAR MAGNETIC RESONANCE; CELL SURFACE; CELL TRACKING; CHEMISTRY; DRUG DELIVERY SYSTEM; DRUG RELEASE; GLIOBLASTOMA; HUMAN; HYPERPOLARIZATION; MOLECULAR BIOLOGY; MOLECULAR IMAGING; MOLECULAR PROBE; NEAR INFRARED SPECTROSCOPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PH; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTON NUCLEAR MAGNETIC RESONANCE; STROMA CELL; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANIMALS; EXTRACELLULAR MATRIX; HUMANS; MAGNETIC RESONANCE IMAGING; MOLECULAR PROBES; NEOPLASM METASTASIS; NEOPLASMS; STROMAL CELLS;

EID: 84879534647     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2980     Document Type: Article

References (86)

1. Stasinopoulos I, Penet MF, Chen Z, Kakkad S, Glunde K, Bhujwalla ZM. Exploiting the tumor microenvironment for theranostic imaging. NMR Biomed. 2011; 24: 636-647.
2. Stasinopoulos I, Penet MF, Krishnamachary B, Bhujwalla ZM. Molecular and functional imaging of invasion and metastasis: windows into the metastatic cascade. Dis. Markers A 2010; 7: 173-188.
3. Pais A, Gunanathan C, Margalit R, Biton IE, Yosepovich A, Milstein D, Degani H. In vivo magnetic resonance imaging of the estrogen receptor in an orthotopic model of human breast cancer. Cancer Res. 2011; 71: 7387-7397.
4. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4: 461-469.
5. Lehrer S, Lee P, Tartter P, Brower S. Tumour HER2 protein in breast cancer and family history. Lancet 1993; 341: 1420-1421.
6. Artemov D, Mori N, Ravi R, Bhujwalla ZM. Magnetic resonance molecular imaging of the HER-2/neu receptor. Cancer Res. 2003; 63: 2723-2727.
7. Clarke RB, Anderson E, Howell A. Steroid receptors in human breast cancer. Trends Endocrinol. Metab. 2004; 15: 316-323.
8. Willcocks D, Toppila M, Hudson CN, Tyler JP, Baird PJ, Eastman CJ. Estrogen and progesterone receptors in human ovarian tumors. Gynecol. Oncol. 1983; 16: 246-253.
9. Medarova Z, Rashkovetsky L, Pantazopoulos P, Moore A. Multiparametric monitoring of tumor response to chemotherapy by noninvasive imaging. Cancer Res. 2009; 69: 1182-1189.
10. Shazeeb MS, Sotak CH, DeLeo M, 3rd, Bogdanov A, Jr. Targeted signal-amplifying enzymes enhance MRI of EGFR expression in an orthotopic model of human glioma. Cancer Res. 2011; 71: 2230-2239.
11. Horak ER, Harris AL, Stuart N, Bicknell R. Angiogenesis in breast cancer. Regulation, prognostic aspects, and implications for novel treatment strategies. Ann. NY Acad. Sci. 1993; 698: 71-84.
12. Pathak AP, Penet MF, Bhujwalla ZM. MR molecular imaging of tumor vasculature and vascular targets. Adv. Genet. 2010; 69: 1-30.
13. 3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 2008; 22: 4179-4189.
14. 3-targeted magnetic resonance imaging. Nat. Med. 1998; 4: 623-626.
15. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang H, Robertson JD, Wickline SA, Lanza GM. Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res. 2003; 63: 5838-5843.
16. Zhang C, Jugold M, Woenne EC, Lammers T, Morgenstern B, Mueller MM, Zentgraf H, Bock M, Eisenhut M, Semmler W, Kiessling F. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Cancer Res. 2007; 67: 1555-1562.
17. Chen W, Jarzyna PA, van Tilborg GA, Nguyen VA, Cormode DP, Klink A, Griffioen AW, Randolph GJ, Fisher EA, Mulder WJ, Fayad ZA. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J. 2010; 24: 1689-1699.
18. 3-rich tumor cells by magnetic resonance imaging. J. Magn. Reson. Imaging 2011; 34: 395-402.
19. Kluza E, Jacobs I, Hectors SJ, Mayo KH, Griffioen AW, Strijkers GJ, Nicolay K. Dual-targeting of α(v)β(3) and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Control. Release 2012; 158: 207-214.
20. Granot D, Addadi Y, Kalchenko V, Harmelin A, Kunz-Schughart LA, Neeman M. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res. 2007; 67: 9180-9189.
21. Arbab AS, Janic B, Knight RA, Anderson SA, Pawelczyk E, Rad AM, Read EJ, Pandit SD, Frank JA. Detection of migration of locally implanted AC133+ stem cells by cellular magnetic resonance imaging with histological findings. FASEB J. 2008; 22: 3234-3246.
22. Mallett CL, McFadden C, Chen Y, Foster PJ. Migration of iron-labeled KHYG-1 natural killer cells to subcutaneous tumors in nude mice, as detected by magnetic resonance imaging. Cytotherapy 2012; 14: 743-751.
23. Chaumeil MM, Gini B, Yang H, Iwanami A, Sukumar S, Ozawa T, Pieper RO, Mischel PS, James CD, Berger MS, Ronen SM. Longitudinal evaluation of MPIO-labeled stem cell biodistribution in glioblastoma using high resolution and contrast-enhanced MR imaging at 14.1 Tesla. Neuro Oncol. 2012; 14: 1050-1061.
24. Partlow KC, Chen J, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, Nolta JA, Caruthers SD, Lanza GM, Wickline SA. 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 2007; 21: 1647-1654.
25. Ahrens ET, Flores R, Xu H, Morel PA. In vivo imaging platform for tracking immunotherapeutic cells. Nature Biotechnol. 2005; 23: 983-987.
26. Ruffell B, Affara NI, Coussens LM. Differential macrophage programming in the tumor microenvironment. Trends Immunol. 2012; 33: 119-126.
27. Shih YY, Hsu YH, Duong TQ, Lin SS, Chow KP, Chang C. Longitudinal study of tumor-associated macrophages during tumor expansion using MRI. NMR Biomed. 2011; 24: 1353-1360.
28. Daldrup-Link HE, Golovko D, Ruffell B, Denardo DG, Castaneda R, Ansari C, Rao J, Tikhomirov GA, Wendland MF, Corot C, Coussens LM. MRI of tumor-associated macrophages with clinically applicable iron oxide nanoparticles. Clin. Cancer Res. 2011; 17: 5695-5704.
29. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625-634.
30. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 2007; 99: 1441-1454.
31. Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br. J. Cancer 1981; 43: 546-550.
32. Chapman JD. The detection and measurement of hypoxic cells in solid tumors. Cancer 1984; 54: 2441-2449.
33. Procissi D, Claus F, Burgman P, Koziorowski J, Chapman JD, Thakur SB, Matei C, Ling CC, Koutcher JA. In vivo 19F magnetic resonance spectroscopy and chemical shift imaging of tri-fluoro-nitroimidazole as a potential hypoxia reporter in solid tumors. Clin. Cancer Res. 2007; 13: 3738-3747.
34. Mason RP, Shukla H, Antich PP. In vivo oxygen tension and temperature: simultaneous determination using 19F NMR spectroscopy of perfluorocarbon. Magn. Reson. Med. 1993; 29: 296-302.
35. 1H NMR approach to quantitative tissue oximetry using hexamethyldisiloxane. Magn. Reson. Med. 2006; 55: 743-748.
36. Ogawa S, Lee TM, Nayak AS, Glynn P. Oxygenation-sensitive contrast in magnetic resonance image of rodent brain at high magnetic fields. Magn. Reson. Med. 1990; 14: 68-78.
37. Neeman M, Dafni H, Bukhari O, Braun RD, Dewhirst MW. In vivo BOLD contrast MRI mapping of subcutaneous vascular function and maturation: validation by intravital microscopy. Magn. Reson. Med. 2001; 45: 887-898.
38. Zhao D, Jiang L, Hahn EW, Mason RP. Comparison of 1H blood oxygen level-dependent (BOLD) and 19F MRI to investigate tumor oxygenation. Magn. Reson. Med. 2009; 62: 357-364.
39. Robey IF, Baggett BK, Kirkpatrick ND, Roe DJ, Dosescu J, Sloane BF, Hashim AI, Morse DL, Raghunand N, Gatenby RA, Gillies RJ. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res. 2009; 69: 2260-2268.
40. Hashim AI, Zhang X, Wojtkowiak JW, Martinez GV, Gillies RJ. Imaging pH and metastasis. NMR Biomed. 2011; 24: 582-591.
41. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J. Nucl. Med. 2008; 49 Suppl. 2: 24S-42S.
42. Fukumura D, Jain RK. Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. J. Cell. Biochem. 2007; 101: 937-949.
43. Gillies RJ, Gatenby RA. Hypoxia and adaptive landscapes in the evolution of carcinogenesis. Cancer Metastasis Rev. 2007; 26: 311-317.
44. 31P MRS as a method of measuring pH in rat tumours. NMR Biomed. 1992; 5: 351-359.
45. 1H MRSI. Magn. Reson. Med. 1999; 41: 743-750.
46. Gillies RJ, Liu Z, Bhujwalla Z. 31P-MRS measurements of extracellular pH of tumors using 3-aminopropylphosphonate. Am. J. Physiol. 1994; 267: C195-203.
47. Provent P, Benito M, Hiba B, Farion R, Lopez-Larrubia P, Ballesteros P, Remy C, Segebarth C, Cerdan S, Coles JA, Garcia-Martin ML. Serial in vivo spectroscopic nuclear magnetic resonance imaging of lactate and extracellular pH in rat gliomas shows redistribution of protons away from sites of glycolysis. Cancer Res. 2007; 67: 7638-7645.
48. Garcia-Martin ML, Martinez GV, Raghunand N, Sherry AD, Zhang S, Gillies RJ. High resolution pH(e) imaging of rat glioma using pH-dependent relaxivity. Magn. Reson. Med. 2006; 55: 309-315.
49. Mason SD, Joyce JA. Proteolytic networks in cancer. Trends Cell Biol. 2011; 21: 228-237.
50. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer Metastasis Rev. 2008; 27: 679-690.
51. Lebel R, Jastrzebska B, Therriault H, Cournoyer MM, McIntyre JO, Escher E, Neugebauer W, Paquette B, Lepage M. Novel solubility-switchable MRI agent allows the noninvasive detection of matrix metalloproteinase-2 activity in vivo in a mouse model. Magn. Reson. Med. 2008; 60: 1056-1065.
52. Olson ES, Jiang T, Aguilera TA, Nguyen QT, Ellies LG, Scadeng M, Tsien RY. Activatable cell penetrating peptides linked to nanoparticles as dual probes for in vivo fluorescence and MR imaging of proteases. Proc. Natl. Acad. Sci. USA 2010; 107: 4311-4316.
53. Tei L, Mazooz G, Shellef Y, Avni R, Vandoorne K, Barge A, Kalchenko V, Dewhirst MW, Chaabane L, Miragoli L, Longo D, Neeman M, Aime S. Novel MRI and fluorescent probes responsive to the Factor XIII transglutaminase activity. Contrast Media Mol. Imaging 2010; 5: 213-222.
54. Robinson SP, Barton SJ, McSheehy PM, Griffiths JR. Nuclear magnetic resonance spectroscopy of cancer. Br. J. Radiol. 1997; 70: S60-S69.
55. Glunde K, Bhujwalla ZM. Metabolic tumor imaging using magnetic resonance spectroscopy. Semin. Oncol. 2011; 38: 26-41.
56. Malloy CR, Sherry AD, Jeffrey FM. Carbon flux through citric acid cycle pathways in perfused heart by 13C NMR spectroscopy. FEBS Lett. 1987; 212: 58-62.
57. Kurhanewicz J, Vigneron DB, Brindle K, Chekmenev EY, Comment A, Cunningham CH, Deberardinis RJ, Green GG, Leach MO, Rajan SS, Rizi RR, Ross BD, Warren WS, Malloy CR. Analysis of cancer metabolism by imaging hyperpolarized nuclei: prospects for translation to clinical research. Neoplasia 2011; 13: 81-97.
58. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-to-noise ratio of >10, 000 times in liquid-state NMR. Proc. Natl. Acad. Sci. USA 2003; 100: 10158-10163.
59. Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. Molecular imaging with endogenous substances. Proc. Natl. Acad. Sci. USA 2003; 100: 10435-10439.
60. Golman K, in 't Zandt R, Thaning M. Real-time metabolic imaging. Proc. Natl. Acad. Sci. USA 2006; 103: 11270-11275.
61. 2]fumarate is a marker of cell necrosis and treatment response in tumors. Proc. Natl. Acad. Sci. USA 2009; 106: 19801-19806.
62. Gallagher FA, Kettunen MI, Day SE, Hu DE, Karlsson M, Gisselsson A, Lerche MH, Brindle KM. Detection of tumor glutamate metabolism in vivo using (13)C magnetic resonance spectroscopy and hyperpolarized [1-(13)C]glutamate. Magn. Reson. Med. 2011; 66: 18-23.
63. 13C label exchange between pyruvate and lactate in tumor cells. J. Biol. Chem. 2011; 286: 24572-24580.
64. 13C-pyruvate imaging reveals alterations in glycolysis that precede c-Myc-induced tumor formation and regression. Cell Metab. 2011; 14: 131-142.
65. Alger JR, Shulman RG. NMR studies of enzymatic rates in vitro and in vivo by magnetization transfer. Q. Rev. Biophys. 1984; 17: 83-124.
66. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J. Magn. Reson. 2000; 143: 79-87.
67. Zhou J, Payen JF, Wilson DA, Traystman RJ, van Zijl PC. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat. Med. 2003; 9: 1085-1090.
68. Gilad AA, McMahon MT, Walczak P, Winnard PT, Jr., Raman V, van Laarhoven HW, Skoglund CM, Bulte JW, van Zijl PC. Artificial reporter gene providing MRI contrast based on proton exchange. Nat. Biotechnol. 2007; 25: 217-219.
69. Lin G, Ho KC, Wang JJ, Ng KK, Wai YY, Chen YT, Chang CJ, Ng SH, Lai CH, Yen TC. Detection of lymph node metastasis in cervical and uterine cancers by diffusion-weighted magnetic resonance imaging at 3T. J. Magn. Reson. Imaging 2008; 28: 128-135.
70. Takahara T, Imai Y, Yamashita T, Yasuda S, Nasu S, Van Cauteren M. Diffusion weighted whole body imaging with background body signal suppression (DWIBS): technical improvement using free breathing, STIR and high resolution 3D display. Radiat. Med. 2004; 22: 275-282.
71. Koh DM, Takahara T, Imai Y, Collins DJ. Practical aspects of assessing tumors using clinical diffusion-weighted imaging in the body. Magn. Reson. Med. Sci. 2007; 6: 211-224.
72. Marchal G, Van Hecke P, Demaerel P, Decrop E, Kennis C, Baert AL, van der Schueren E. Detection of liver metastases with superparamagnetic iron oxide in 15 patients: results of MR imaging at 1.5 T. Am. J. Roentgenol. 1989; 152: 771-775.
73. Weissleder R, Elizondo G, Josephson L, Compton CC, Fretz CJ, Stark DD, Ferrucci JT. Experimental lymph node metastases: enhanced detection with MR lymphography. Radiology 1989; 171: 835-839.
74. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, de la Rosette J, Weissleder R. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 2003; 348: 2491-2499.
75. Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin. Imaging 2009; 33: 301-305.
76. Motosugi U, Ichikawa T, Sou H, Sano K, Tominaga L, Kitamura T, Araki T. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J. Magn. Reson. Imaging 2009; 30: 1042-1046.
77. Kim YK, Lee MW, Lee WJ, Kim SH, Rhim H, Lim JH, Choi D, Kim YS, Jang KM, Lee SJ, Lim HK. Diagnostic accuracy and sensitivity of diffusion-weighted and of gadoxetic acid-enhanced 3-T MR imaging alone or in combination in the detection of small liver metastasis (≤1.5 cm in diameter). Invest. Radiol. 2012; 47: 159-166.
78. Kato Y, Okollie B, Artemov D. Noninvasive 1H/13C magnetic resonance spectroscopic imaging of the intratumoral distribution of temozolomide. Magn. Reson. Med. 2006; 55: 755-761.
79. 2* effect of iron particles. Magn. Reson. Med. 2009; 61: 1059-1065.
80. Jain TK, Foy SP, Erokwu B, Dimitrijevic S, Flask CA, Labhasetwar V. Magnetic resonance imaging of multifunctional pluronic stabilized iron-oxide nanoparticles in tumor-bearing mice. Biomaterials 2009; 30: 6748-6756.
81. Kircher MF, de la Zerda A, Jokerst JV, Zavaleta CL, Kempen PJ, Mittra E, Pitter K, Huang R, Campos C, Habte F, Sinclair R, Brennan CW, Mellinghoff IK, Holland EC, Gambhir SS. A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle. Nat. Med. 2012; 18: 829-834.
82. Xie J, Chen K, Huang J, Lee S, Wang J, Gao J, Li X, Chen X. PET/NIRF/MRI triple functional iron oxide nanoparticles. Biomaterials 2010; 31: 3016-3022.
83. Li C, Penet MF, Winnard P, Jr., Artemov D, Bhujwalla ZM. Image-guided enzyme/prodrug cancer therapy. Clin. Cancer Res. 2008; 14: 515-522.
84. Li C, Penet MF, Wildes F, Takagi T, Chen Z, Winnard PT, Artemov D, Bhujwalla ZM. Nanoplex delivery of siRNA and prodrug enzyme for multimodality image-guided molecular pathway targeted cancer therapy. ACS Nano 2010; 4: 6707-6716.
85. Kumar M, Yigit M, Dai G, Moore A, Medarova Z. Image-guided breast tumor therapy using a small interfering RNA nanodrug. Cancer Res. 2010; 70: 7553-7561.
86. 3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 2008; 22: 2758-2767.